Mofest is an antibiotic belongs to 3rd group of fluoroquinolones Fluoroquinolones are potent bactericidal agents against E. coli and various species of Salmonella, Shigella, Enterobacter, Campylobacter and Neisseeria, it has excellent activity against S. pneumoniae, Mofest is used in respiratory tract infections, in urinary tract infectionsand in bone and soft tissue infections.
Mofest is primarily indicated in conditions like Acute bacterial sinusitis, Chronic bronchitis, Lower respiratory tract infections, Oedema, Pneumonia, Short-term treatment of severe congestive heart failure, Sinusitis, Skin infections, Soft tissue infections, Upper respiratory tract infections, and can also be given in adjunctive therapy as an alternative drug of choice in Bacterial conjunctivitis.
Mofest is contraindicated in conditions like Heart failure, Bradycardia, Liver diseases,Electrolyte disturbance.
The severe or irreversible adverse effects of Mofest, which give rise to further complications include Hypotension, Hypotension, Hyperglycemia, Dyspnea, Hyperuricemia, Hyperglycemia, Hyperlipidemia. Mofest produces potentially life-threatening effects which include Anaphylactic reactions, Atrial fibrillation, which are responsible for the discontinuation of Mofest therapy. The symptomatic adverse reactions produced by Mofest are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Drowsiness, Nausea, vomiting, Diarrhea, Myalgia, Restlessness, Tachycardia, Tremors, Insomnia, Abdominal pain, Sweating, Skin rash, Dyspepsia, Pseudomembranous colitis, Hemolytic anemia, Thrombocytopenia, Edema, Hot flushes, Syncope, Gynecomastia, Abnormal LFT, Hypersensitivity reactions, Taste perversion, Superinfection, QT prolongation, Visual disturbances, dizziness, dyspepsia, Abnormal LFT, agranulocytosis, arthropathy, Tachycardia.
It should be used with caution in patients with known or suspected central nervous system disorders which may predispose to seizures or lower the seizure threshold As no pharmacokinetics or pharmacodynamic data are available in severe hepatic impairment, the use of Mofest in this patients group is not recommended. Mofest should be used with caution in patients with known QT interval prolongation or uncorrected hypokalemia, in those receiving class IA (e.g quinidine or procaine amide) or class Ill antiarrhythmic agents (sotalol, ibutilide, amiodarone): and in patients who are receiving other agents known to increase the QT interval (e.g erythromycin, tricyclic antidepressants).